NASDAQ:VSTM Verastem (VSTM) Stock Price, News & Analysis $2.83 +0.12 (+4.43%) (As of 09/19/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Verastem alerts: Email Address About Verastem Stock (NASDAQ:VSTM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Verastem alerts:Sign Up Key Stats Today's Range$2.73▼$2.8850-Day Range$2.20▼$3.6852-Week Range$2.10▼$14.22Volume478,059 shsAverage Volume496,513 shsMarket Capitalization$113.88 millionP/E RatioN/ADividend YieldN/APrice Target$14.83Consensus RatingBuy Company OverviewVerastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.Read More… Why You Should NOT Trade This Market (Ad)You'll be interested in our 5-Day Options Trading Challenge, starting September 23. So, what makes this different from every other options research you may have seen? Well, for starters... most of them want you to first BUY their service... which is usually thousands of dollars...Just click here to get the full details on the 5-Day Options Trading Challenge, before this offer go Verastem Stock Analysis - MarketRank™See Top Rated MarketRank™ StocksOverall MarketRank™: 46th PercentileVerastem scored higher than 46% of companies evaluated by MarketBeat, and ranked 675th out of 1,007 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingVerastem has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageVerastem has only been the subject of 4 research reports in the past 90 days.Read more about Verastem's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Verastem are expected to grow in the coming year, from ($3.36) to ($2.60) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Verastem is -0.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Verastem is -0.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVerastem has a P/B Ratio of 1.25. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Verastem's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.71% of the float of Verastem has been sold short.Short Interest Ratio / Days to CoverVerastem has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Verastem has recently increased by 6.60%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVerastem does not currently pay a dividend.Dividend GrowthVerastem does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted5.71% of the float of Verastem has been sold short.Short Interest Ratio / Days to CoverVerastem has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Verastem has recently increased by 6.60%, indicating that investor sentiment is decreasing significantly. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Verastem this week, compared to 3 articles on an average week.Search Interest17 people have searched for VSTM on MarketBeat in the last 30 days. This is an increase of 113% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Verastem insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $107.00 in company stock.Percentage Held by InsidersOnly 2.20% of the stock of Verastem is held by insiders.Percentage Held by Institutions88.37% of the stock of Verastem is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Verastem's insider trading history. Receive VSTM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Verastem and its competitors with MarketBeat's FREE daily newsletter. Email Address VSTM Stock News HeadlinesComparing Verastem (NASDAQ:VSTM) and Kaya (OTCMKTS:KAYS)September 14, 2024 | americanbankingnews.comVerastem Oncology to Present at the 2024 Cantor Global Healthcare ConferenceSeptember 10, 2024 | businesswire.comWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…September 19, 2024 | Porter & Company (Ad)Verastem's Path To FDA Approval: High-Risk, High-Reward Oncology OpportunitySeptember 6, 2024 | seekingalpha.comVerastem Oncology and STAAR Ovarian Cancer Foundation Establish the Inaugural Low-Grade Serous Ovarian Cancer (LGSOC) Awareness Day on September 9, 2024September 3, 2024 | financialpost.comOutperform Rating and $7 Target for Verastem Amidst LGSOC Treatment Potential and Stock Valuation OpportunityAugust 22, 2024 | markets.businessinsider.comBuy Rating Affirmed for Verastem: Financial Stability and Promising Drug Pipeline Fuel OptimismAugust 12, 2024 | markets.businessinsider.comVerastem Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business UpdatesAugust 9, 2024 | finance.yahoo.comSee More Headlines VSTM Stock Analysis - Frequently Asked Questions How have VSTM shares performed this year? Verastem's stock was trading at $8.14 at the beginning of the year. Since then, VSTM stock has decreased by 65.2% and is now trading at $2.83. View the best growth stocks for 2024 here. How were Verastem's earnings last quarter? Verastem, Inc. (NASDAQ:VSTM) released its quarterly earnings data on Thursday, August, 8th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, beating the consensus estimate of ($1.06) by $0.75. The biopharmaceutical company earned $10 million during the quarter. When did Verastem's stock split? Verastem shares reverse split on Thursday, June 1st 2023. The 1-12 reverse split was announced on Thursday, June 1st 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. Who are Verastem's major shareholders? Verastem's top institutional investors include Nantahala Capital Management LLC (0.99%), Bank of New York Mellon Corp (0.27%), Rhumbline Advisers (0.11%) and Acadian Asset Management LLC (0.11%). Insiders that own company stock include Brian M Stuglik, Dan Paterson, Daniel Calkins and Robert E Gagnon. View institutional ownership trends. How do I buy shares of Verastem? Shares of VSTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Verastem own? Based on aggregate information from My MarketBeat watchlists, some other companies that Verastem investors own include TherapeuticsMD (TXMD), Micron Technology (MU), Novavax (NVAX), Inovio Pharmaceuticals (INO), Gilead Sciences (gild), Sorrento Therapeutics (SRNE) and SCYNEXIS (SCYX). Company Calendar Last Earnings8/08/2024Today9/19/2024Next Earnings (Estimated)11/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:VSTM CUSIP92337C10 CIK1526119 Webwww.verastem.com Phone(781) 292-4200FaxN/AEmployees50Year FoundedN/APrice Target and Rating Average Stock Price Target$14.83 High Stock Price Target$27.00 Low Stock Price Target$7.00 Potential Upside/Downside+422.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($4.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-87,370,000.00 Net MarginsN/A Pretax Margin-894.91% Return on Equity-194.05% Return on Assets-64.48% Debt Debt-to-Equity Ratio1.88 Current Ratio3.28 Quick Ratio3.28 Sales & Book Value Annual Sales$2.60 million Price / Sales43.95 Cash FlowN/A Price / Cash FlowN/A Book Value$2.27 per share Price / Book1.25Miscellaneous Outstanding Shares40,240,000Free Float24,769,000Market Cap$114.28 million OptionableOptionable Beta0.16 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report This page (NASDAQ:VSTM) was last updated on 9/19/2024 by MarketBeat.com Staff From Our PartnersThis diversified cannabis pioneer could make huge moves soonThe cannabis industry seems deeply saturated, so how do you know where to best invest your money? Let’s start ...Greenlane | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | SponsoredForget ChatGPT: Follow the AI Retirement PlaybookEveryone’s talking about AI right now, but I’ve been talking about it for years. Follow this two-part playb...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verastem, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verastem With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.